Hikal Ltd

Hikal Ltd Share Price Today: Live Updates & Key Insights

Get insights on Hikal Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Hikal Ltd Share Price Chart

Hikal Ltd Fundamentals

Traded Volume: 3,06,935

Market Cap(Cr): 2,774

Avg Traded Price 223.80

1 Year return -41.82%

Upper Circuit 228.4

Lower Circuit 220.1

P/E TTM 275.00

P/B Ratio 1.00

Traded Value(Cr) 690.54

EPS TTM 0.819

Book value 0.819

Dividend 1.00%

Hikal Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Hikal Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Hikal Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -6.40%

1M -6.76%

3M -13.00%

1Y -41.82%

YTD -43.32%

Hikal Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Hikal Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 1.26L

Day Before Yesterday 1.44L

1W Avg 2.27L

1M Avg 1.51L

3M Avg 3.47L

Hikal Ltd Technical Details

Hikal Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 221

Support 2 216

Support 3 212

Pivot Point : 224

Resistance 1 229

Resistance 2 233

Resistance 3 237

Hikal Ltd Corporate Actions

Hikal Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Hikal Ltd’s capital allocation strategies.

All

Ex-Date 02-Sep-2025 Type D Description 0.80/share@40.00% Record Date 02-Sep-2025 Ratio 40.00

Ex-Date 07-Feb-2025 Type D Description 0.60/share@30.00% Record Date 08-Feb-2025 Ratio 30.00

Ex-Date 04-Sep-2024 Type D Description 0.60/share@30.00% Record Date 04-Sep-2024 Ratio 30.00

Ex-Date 20-Feb-2024 Type D Description 0.60/share@30.00% Record Date 20-Feb-2024 Ratio 30.00

Ex-Date 18-Sep-2023 Type D Description 0.60/share@30.00% Record Date 19-Sep-2023 Ratio 30.00

Ex-Date 14-Feb-2023 Type D Description 0.60/share@30.00% Record Date 14-Feb-2023 Ratio 30.00

Ex-Date 14-Sep-2022 Type D Description 0.40/share@20.00% Record Date 15-Sep-2022 Ratio 20.00

Ex-Date 23-Feb-2022 Type D Description 1.20/share@60.00% Record Date 24-Feb-2022 Ratio 60.00

Ex-Date 25-Aug-2021 Type D Description 1.00/share@50.00% Record Date 26-Aug-2021 Ratio 50.00

Ex-Date 15-Feb-2021 Type D Description 1.00/share@50.00% Record Date 16-Feb-2021 Ratio 50.00

Ex-Date 07-Sep-2020 Type D Description 0.20/share@10.00% Record Date - Ratio 10.00

Ex-Date 17-Feb-2020 Type D Description 1.00/share@50.00% Record Date 18-Feb-2020 Ratio 50.00

Ex-Date 23-Jul-2019 Type D Description 0.60/share@30.00% Record Date - Ratio 30.00

Ex-Date 13-Feb-2019 Type D Description 0.60/share@30.00% Record Date 14-Feb-2019 Ratio 30.00

Ex-Date 31-Jul-2018 Type D Description 0.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 22-Jun-2018 Type B Description share@1:2 Record Date 25-Jun-2018 Ratio 1:2

Ex-Date 21-Feb-2018 Type D Description 0.70/share@35.00% Record Date 22-Feb-2018 Ratio 35.00

Ex-Date 02-Aug-2017 Type D Description 0.60/share@30.00% Record Date - Ratio 30.00

Ex-Date 13-Feb-2017 Type D Description 0.60/share@30.00% Record Date 14-Feb-2017 Ratio 30.00

Ex-Date 02-Aug-2016 Type D Description 0.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 17-May-2016 Type D Description 0.50/share@25.00% Record Date 18-May-2016 Ratio 25.00

Ex-Date 04-Aug-2015 Type D Description 0.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 18-May-2015 Type D Description 0.50/share@25.00% Record Date 19-May-2015 Ratio 25.00

Ex-Date 27-Feb-2015 Type S Description share@1:5.00 Record Date 02-Mar-2015 Ratio 1:5.00

Ex-Date 14-Aug-2014 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 18-Feb-2014 Type D Description 2.00/share@20.00% Record Date 20-Feb-2014 Ratio 20.00

Ex-Date 13-Aug-2013 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 14-Aug-2012 Type D Description 6.00/share@60.00% Record Date - Ratio 60.00

Ex-Date 09-Aug-2011 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00

Ex-Date 24-May-2011 Type D Description 3.00/share@30.00% Record Date 25-May-2011 Ratio 30.00

Ex-Date 09-Aug-2010 Type D Description 4.00/share@40.00% Record Date - Ratio 40.00

Ex-Date 11-May-2010 Type D Description 4.00/share@40.00% Record Date 12-May-2010 Ratio 40.00

Ex-Date 11-Aug-2008 Type D Description 4.00/share@40.00% Record Date - Ratio 40.00

Ex-Date 31-Jan-2008 Type D Description 3.00/share@30.00% Record Date 01-Feb-2008 Ratio 30.00

Ex-Date 13-Aug-2007 Type D Description 3.50/share@35.00% Record Date - Ratio 35.00

Ex-Date 14-Feb-2007 Type D Description 3.00/share@30.00% Record Date 15-Feb-2007 Ratio 30.00

Dividends

Announcement Date 02-Sep-2025 Ex Dividend Date 02-Sep-2025 Dividend(%) 40

Announcement Date 07-Feb-2025 Ex Dividend Date 07-Feb-2025 Dividend(%) 30

Announcement Date 04-Sep-2024 Ex Dividend Date 04-Sep-2024 Dividend(%) 30

Announcement Date 20-Feb-2024 Ex Dividend Date 20-Feb-2024 Dividend(%) 30

Announcement Date 18-Sep-2023 Ex Dividend Date 18-Sep-2023 Dividend(%) 30

Announcement Date 14-Feb-2023 Ex Dividend Date 14-Feb-2023 Dividend(%) 30

Announcement Date 14-Sep-2022 Ex Dividend Date 14-Sep-2022 Dividend(%) 20

Announcement Date 23-Feb-2022 Ex Dividend Date 23-Feb-2022 Dividend(%) 60

Announcement Date 25-Aug-2021 Ex Dividend Date 25-Aug-2021 Dividend(%) 50

Announcement Date 15-Feb-2021 Ex Dividend Date 15-Feb-2021 Dividend(%) 50

Announcement Date 07-Sep-2020 Ex Dividend Date 07-Sep-2020 Dividend(%) 10

Announcement Date 17-Feb-2020 Ex Dividend Date 17-Feb-2020 Dividend(%) 50

Announcement Date 23-Jul-2019 Ex Dividend Date 23-Jul-2019 Dividend(%) 30

Announcement Date 13-Feb-2019 Ex Dividend Date 13-Feb-2019 Dividend(%) 30

Announcement Date 31-Jul-2018 Ex Dividend Date 31-Jul-2018 Dividend(%) 25

Announcement Date 21-Feb-2018 Ex Dividend Date 21-Feb-2018 Dividend(%) 35

Announcement Date 02-Aug-2017 Ex Dividend Date 02-Aug-2017 Dividend(%) 30

Announcement Date 13-Feb-2017 Ex Dividend Date 13-Feb-2017 Dividend(%) 30

Announcement Date 02-Aug-2016 Ex Dividend Date 02-Aug-2016 Dividend(%) 25

Announcement Date 17-May-2016 Ex Dividend Date 17-May-2016 Dividend(%) 25

Announcement Date 04-Aug-2015 Ex Dividend Date 04-Aug-2015 Dividend(%) 25

Announcement Date 18-May-2015 Ex Dividend Date 18-May-2015 Dividend(%) 25

Announcement Date 14-Aug-2014 Ex Dividend Date 14-Aug-2014 Dividend(%) 25

Announcement Date 18-Feb-2014 Ex Dividend Date 18-Feb-2014 Dividend(%) 20

Announcement Date 13-Aug-2013 Ex Dividend Date 13-Aug-2013 Dividend(%) 25

Announcement Date 14-Aug-2012 Ex Dividend Date 14-Aug-2012 Dividend(%) 60

Announcement Date 09-Aug-2011 Ex Dividend Date 09-Aug-2011 Dividend(%) 30

Announcement Date 24-May-2011 Ex Dividend Date 24-May-2011 Dividend(%) 30

Announcement Date 09-Aug-2010 Ex Dividend Date 09-Aug-2010 Dividend(%) 40

Announcement Date 11-May-2010 Ex Dividend Date 11-May-2010 Dividend(%) 40

Announcement Date 11-Aug-2008 Ex Dividend Date 11-Aug-2008 Dividend(%) 40

Announcement Date 31-Jan-2008 Ex Dividend Date 31-Jan-2008 Dividend(%) 30

Announcement Date 13-Aug-2007 Ex Dividend Date 13-Aug-2007 Dividend(%) 35

Announcement Date 14-Feb-2007 Ex Dividend Date 14-Feb-2007 Dividend(%) 30

Bonus

Record Date 25-Jun-2018 Ex-Bonus Date 22-Jun-2018 Ratio 1:2

Splits

Record Date 02-Mar-2015 Split Date 27-Feb-2015 Face Value (Before/After) 10.00/2.00

Others

Rights No Rights has been declared by HIKAL

Hikal Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Hikal Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Hikal Ltd's relative performance and valuation against major competitors.

Stock Name RPG Life Sciences Ltd ₹2254.00 (+1.30%) M. Cap (Cr) 37.28 1 Yr Return (%) +10.91% P/E (TTM) 17.31 PB Ratio 9.83

Stock Name Gufic BioSciences Ltd ₹352.45 (+2.86%) M. Cap (Cr) 35.34 1 Yr Return (%) -13.10% P/E (TTM) 62.10 PB Ratio 6.16

Stock Name Unichem Laboratories Ltd ₹466.40 (-2.48%) M. Cap (Cr) 32.84 1 Yr Return (%) -45.80% P/E (TTM) 37.12 PB Ratio 1.34

Stock Name Hikal Ltd ₹224.98 (-1.46%) M. Cap (Cr) 27.74 1 Yr Return (%) -41.82% P/E (TTM) 274.66 PB Ratio 2.20

Stock Name IOL Chemicals & Pharmaceuticals Ltd ₹90.32 (-1.42%) M. Cap (Cr) 26.51 1 Yr Return (%) +32.14% P/E (TTM) 22.88 PB Ratio 1.60

Stock Name Alembic Ltd ₹98.51 (-0.44%) M. Cap (Cr) 25.30 1 Yr Return (%) -20.08% P/E (TTM) 7.81 PB Ratio 1.08

Stock Name SMS Pharmaceuticals Ltd ₹281.90 (-0.70%) M. Cap (Cr) 26.40 1 Yr Return (%) +17.80% P/E (TTM) 29.62 PB Ratio 4.43

Hikal Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Hikal Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 280.40 Mar 2024 186.62 Mar 2023 315.29 Mar 2022 293.73 Mar 2021 229.02

PARTICULARS Investing Activities Mar 2025 -136.50 Mar 2024 -173.74 Mar 2023 -292.34 Mar 2022 -284.37 Mar 2021 -156.20

PARTICULARS Financing Activities Mar 2025 -143.60 Mar 2024 -27.00 Mar 2023 -7.68 Mar 2022 -5.56 Mar 2021 -96.87

PARTICULARS Net Cash Flow Mar 2025 0.30 Mar 2024 -14.12 Mar 2023 15.27 Mar 2022 3.80 Mar 2021 -24.05

Hikal Ltd Shareholding Pattern

This shows the ownership breakdown of Hikal Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 68.85%

Public 21.75%

Other Institutions 1.06%

FII 4.23%

Mutual Funds 4.09%

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals. The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India. It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division. Within pharmaceutical division, it offer human health and animal health products.Hikal commenced its first project in 1991 at its first greenfield site at M.I.D.C., Mahad with the manufacture of intermediates for agrochemical industry. It also bagged first big contract with Hoechst. During 1996, Company came with public issue to part finance the expansion project of Thiabendazol. It achieved another milestone when Merck & Co., USA chose Hikal as a partner to outsource Thiabendazole (TBZ, a fungicide). Since the capacity at Mahad was inadequate, Hikal built second greenfield site, a state-of-the-art manufacturing facility at Taloja in 1997. The Company has been accorded Export House status by the Government of India. It set up a new manufacturing facility near Mumbai in collaboration with Merck & Co Inc, USA, for the manufacture of a post-harvest fungicide. It received the prestigious '5 star Safety Award' from British Safety Council' UK for high standards maintained at the Taloja Site.During 1999-2000, the company has acquired an Agrochemical manufacturing site at Panoli, Gujarat from Novartis India Limited. The Company's status as an Export House has been elevated to that of a Trading House. In 2001, it entered the pharmaceuticals business, when it acquired the R&D Unit and Bulk Drug Manufacturing Facility of Wintac Ltd at Bangalore in Karnataka. In 2004, it built a brand new API plant post-acquisition and received USFDA certification. The Bangalore API Plant approved by USFDA and Australian TGA. During 2004-05, A 100% EOU plant for pharamaceutical intermediates is being set up. This unit is expected to be operational in the first half of the coming year. During 2004-05, the company is establishing a state-of-the-art R&D facility in Pune and this research facility is expected to be operational in early 2006.In Aug. 2004, the company has entered into an agreement with Bayer CropScience AG to manufacture and supply Agro biochemical intermediates and has set up a plant to manufacture this products in Mahad Plant. In 2005, the company made an agreement with Crompton Corporation, USA to manufacture and market a New Generation Crop protection product. In Nov. 2005, the company entered into a JV agreement with a subsidiary company of Sinochem Corporation, China.During 2005-2006, the company made a strategic investment in Jiangsu Chemstar Industries Co (a subsidiary company of Sinochem Corporation China A Fortune 500 company). The company acquired 10% stake in the year. The companies production capacity of Crop protection products and Pharmaceutical products stood at 4436 MTn and 180 MT respectively. The Company commenced export of Gabapentine to the US and Canada markets during FY 2006-07. It acquired Marsing & Co. A/S, Denmark and commenced marketing and distribution of APIs in various countries. The Company increased investment to 16% in Jiangsu Chemstar Industries Co. Ltd., (a subsidiary company of Sinochem Corporation, China A FORTUNE 500 company) in FY'2007. During the year, it started supply of new Crop Protection product to one of the leading multinational companies. In Pharma plant, its existing Intermediate products registered increase in volumes and two new Pharma products were manufactured at Panoli site. R&D unit labs got upgraded and two new labs were added during the year 2007-08.In 2008, the Company established Acoris Research Ltd., a contract research facility at the International Biotech Park, Pune, which is fully operational. In 2009, it expanded manufacturing capabilities. Construction of the new multi-purpose active ingredients plant for crop protection at the Taloja site was completed. It commissioned several new multipurpose API plants at the US FDA approved site in Bangalore. It commissioned a new multipurpose pharma intermediates plant at Panoli. Long-term contracts with global life sciences companies had a substantial impact on business. It signed long-term contract for a patented molecule with a leading multinational company.As per the Scheme of Arrangement effective from 1st April 2012, the Research and Development activity of Acoris demerged with Hika. Acoris formerly a subsidiary is now a division of Hikal and further strengthened its capabilities, both in terms of manpower as well as technical capabilities.During the year 2013, it signed a manufacturing agreement with a specialty US based food ingredient company. It completed initial supplies for advanced intermediates to one of the largest U.S. biotech companies. It signed a contract with a leading Japanese company to develop different peptides using their proprietary technology. In December 2016, Company sold its stake in subsidiary, Hikal International B.V. In 2017, it sold the R&D unit in Bangalore. The Company issued Bonus Shares on 26 June 2018 in the ratio of 1:2 i.e. one bonus equity share of Rs. 2/- each fully paid-up for every two existing equity shares of Rs. 2/- each fully paid-up held by the members.In 2023, new product launches in the antidiabetic therapeutic area gained significant traction among global customers. The Company made significant progress on the multi-year Animal Health project with a leading global innovator on developing product portfolio.The new Animal Health Multi-Purpose facility commissioned at Panoli, Gujarat in FY 2024. The Company introduced a Specialty Chemicals portfolio to enhance asset productivity and expand into high-value, differentiated segments in FY 2025. It launched two new sub-category brands, HiZenn for Personal Care and HiFend for Biocide in 2025.

Non-Exec & Non-Independent Dir

Baba Kalyani

Registered office 717/718 Maker Chamber V, 7th Floor Nariman Point, Mumbai, Maharashtra, 400021

FAX :91-022-3926 7100/62770477

Background

Incorporation Year 1988

Face Value ₹2.00

Market Lot 1

Hikal Ltd Latest News

VIEW MORE NEWS

FAQs on Hikal Ltd